ClinicalTrials.gg
CompletedNCT02309671Updated Dec 14, 2020

A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment

A Phase 2 interventional study of FE 999049 and follitropin beta in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 1 site in Japan. Open to female participants aged 20 Years to 39 Years. Per ClinicalTrials.gov, last updated 2020-12-14.

Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
20 Years to 39 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing follitropin delta in Infertility — 1 open to participants now, 1 under way, none of them phase 3. follitropin delta · Infertility.

Enrollment
9th of 13
159 · median 220
Started
2014
with 1 other
Phase 2
5 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
10 of 13
Ferring Pharmaceuticals

Among the 13 studies testing follitropin delta in Infertility, this one is the 9th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 4th registered.

Infertility

2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

1 of the 13 studies testing follitropin delta in Infertility is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About follitropin delta

follitropin delta: first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 20 Years to 39 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing follitropin delta in Infertility, or all of them as a file.
02

Study summary

This trial investigates the effects of several doses of FE 999049 in Japanese women undergoing IVF/ICSI treatment.

03

Conditions studied

  • Infertility

Browse trials for

04

Who can participate

Ages eligible
20 Years to 39 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women diagnosed with tubal infertility, unexplained infertility, infertility related to endometriosis stage I/II or with partners diagnosed with male factor infertility
  • Women eligible for IVF and/or ICSI treatment
  • Women aged 20-39 years
  • Women with (BMI) of 17.5-32.0 kg/m2

Exclusion criteria

Exclusion Criteria:

  • Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis stage III/IV
  • Women with history of recurrent miscarriage
  • Women with to controlled ovarian stimulation with gonadotropins
  • Women with three or more controlled ovarian stimulation cycles
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    FE 999049 6 µg

    Drug: FE 999049

  • Experimental
    FE 999049 9 µg

    Drug: FE 999049

  • Experimental
    FE 999049 12 µg

    Drug: FE 999049

  • Active comparator
    FOLLISTIM 150 IU

    follitropin beta

    Drug: follitropin beta

Interventions

06

What researchers measure

Primary outcomes

  1. Number of oocytes retrieved

    Time frame: End of stimulation (max 16 days after investigational medicinal product (IMP) start)

Secondary outcomes

  1. Number of follicles during stimulation

    Time frame: Up to 16 days

  2. Size of follicles during stimulation

    Time frame: Up to 16 days

  3. Endocrine profile measured by circulating levels of hormones

    Time frame: Up to 16 days

  4. Total IMP dose administered measured from first until last dose (end of stimulation)

    Time frame: Up to 16 days

  5. Embryo quality measured by fertilised oocytes and number and quality of embryos and blastocysts during culturing

    Time frame: 5 days (from oocyte retrieval to embryo transfer)

  6. Successful pregnancy rate

    Time frame: 5-6 weeks after transfer

  7. Frequency of adverse events

    Time frame: From signing informed consent form until end of trial visit = 8-9 weeks

  8. Intensity of adverse events

    Time frame: From signing informed consent form until end of trial visit = 8-9 weeks

07

Study locations

1 site
  • Investigational site (there may be other sites in this country)
    Tokyo, Japan
08

References and documents

Publications

  • Ishihara O, Klein BM, Arce JC; Japanese Follitropin Delta Phase 2 Trial Group. Randomized, assessor-blind, antimullerian hormone-stratified, dose-response trial in Japanese in vitro fertilization/intracytoplasmic sperm injection patients undergoing controlled ovarian stimulation with follitropin delta. Fertil Steril. 2021 Jun;115(6):1478-1486. doi: 10.1016/j.fertnstert.2020.10.059. Epub 2020 Dec 4. PubMed 33272623 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2014, a primary completion of Nov 2015 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2014
First posted
Dec 5, 2014
Start
Dec 2014
Primary completionActual
Nov 2015
CompletionActual
Sep 2016
Results delay requested
Nov 4, 2016
Last update
Dec 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02309671
Responsible party
Sponsor
First posted
Dec 5, 2014
Start date
Dec 2014
Primary completion
Nov 2015
Completion
Sep 2016
Last update
Dec 14, 2020

Study contacts

Clinical Development Support
study director · Ferring Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin delta

Start the discussion